Literature DB >> 18553158

Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.

Maria G Ioannou1, Efstathios Stathakis, Andreas C Lazaris, Thomas Papathomas, Evangelos Tsiambas, George K Koukoulis.   

Abstract

We histologically and immunohistochemically studied 95 bone marrow (BM) reactive plasmacytoses. Ten biopsies from plasma cell myeloma (PCM) patients served as a control group. In addition, we studied 10 monoclonal gammopathy of undetermined significance (MGUS) cases. Histologically, plasmacytosis varied between 5% and 25% with an interstitial pattern of plasma cell (PC) distribution being characteristically displayed. Immunohistochemically, we did not find any CD56/NCAM nor cyclin D1 expression in all biopsies (95 of 95, 100%), not even a weak, doubtful one; PCs were all polyclonal and CD138 positive. On the contrary, myeloma-associated PCs showed monoclonality for kappa- or lambda- light chain and strong CD56/NCAM immunoreactivity (8 of 10, 80%); four of them were cyclin D1 positive. Osteoblasts exhibited similar CD56/NCAM expression in both groups. Our data confirm the diagnostic utility of CD56/NCAM in the phenotypic characterization of polyclonal plasma cells, suggesting an important role of this particular immunomarker in the BM trephine study of polyclonal versus neoplastic plasmacytic infiltrations.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18553158     DOI： 10.1007/s12253-008-9069-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  21 in total

1.  Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).

Authors:  B Van Camp; B G Durie; C Spier; M De Waele; I Van Riet; E Vela; Y Frutiger; L Richter; T M Grogan
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

2.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.

Authors:  Marcus Kremer; German Ott; Michaela Nathrath; Katja Specht; Katrin Stecker; Christoph Alexiou; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

3.  Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.

Authors:  A Rawstron; S Barrans; D Blythe; F Davies; A English; G Pratt; A Child; G Morgan; A Jack
Journal:  Br J Haematol       Date:  1999-01       Impact factor: 6.998

Review 4.  Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.

Authors:  Marcus Kremer; Leticia Quintanilla-Martínez; Jörg Nährig; Christoph von Schilling; Falko Fend
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

5.  Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Authors:  C Pellat-Deceunynck; S Barillé; D Puthier; M J Rapp; J L Harousseau; R Bataille; M Amiot
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

6.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors:  C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

7.  Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation.

Authors:  S Sukpanichnant; J B Cousar; A Leelasiri; S E Graber; J P Greer; R D Collins
Journal:  Hum Pathol       Date:  1994-03       Impact factor: 3.466

8.  Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.

Authors:  Cherie Hilborn Dunphy; Melanie Kandt Nies; Don Alexander Gabriel
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-09

9.  Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.

Authors:  P Martín; A Santón; C Bellas
Journal:  Histopathology       Date:  2004-04       Impact factor: 5.087

10.  Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.

Authors:  Naohi Sahara; Akihiro Takeshita; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Takeshita; Kensuke Naito; Michio Ihara; Takaaki Ono; Sadahiro Tamashima; Kenji Nara; Kazunori Ohnishi; Ryuzo Ohno
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998
View more
  4 in total

1.  Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.

Authors:  Katherine R Calvo; Donald C Vinh; Irina Maric; Weixin Wang; Pierre Noel; Maryalice Stetler-Stevenson; Diane C Arthur; Mark Raffeld; Amalia Dutra; Evgenia Pak; Kyungjae Myung; Amy P Hsu; Dennis D Hickstein; Stefania Pittaluga; Steven M Holland
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

Review 2.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

3.  GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.

Authors:  Karthik A Ganapathi; Danielle M Townsley; Amy P Hsu; Diane C Arthur; Christa S Zerbe; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Sergio D Rosenzweig; Raul C Braylan; Neal S Young; Steven M Holland; Katherine R Calvo
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

4.  Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study.

Authors:  Jasmita Dass; Sudheer Arava; Pravas Chandra Mishra; Amit Kumar Dinda; Hara Prasad Pati
Journal:  South Asian J Cancer       Date:  2019 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.